Tag: psychedelics

DEA Approves Church’s Petition To Use Psychedelics In Religious Ceremonies Without The Need For A Lawsuit

A Washington State church says the Drug Enforcement Administration (DEA) has approved its application for an exception under federal drug laws to use the psychedelic ayahuasca in religious ceremonies—and, for the first time, the agency granted the unique exemption without legal challenges.

The Church of Gaia on Friday said DEA approved a petition for congregants to use ayahuasca under the Religious Freedom Restoration Act (RFRA), which was enacted in 2009 to create a pathway for religious organizations to request a carve-out under the Controlled Substances Act (CSA).

There have been relatively few examples of DEA approving such petitions in the years since—and churches that have sought the exemption have had to engage in litigation against the federal government over their requests. Uniquely, approval for this latest petition was granted without the need for lawsuits, as Mason Marks of Psychedelic Week first reported.

“As the sacrament for the Church of Gaia, Ayahuasca serves as a profound ceremonial tool for accessing spiritual connection and abundance,” Connor Mize, founder of the church, said in a press release. “In pursuing the religious exemption, we aimed to ensure the safety of the church’s members, Indigenous elders, and leaders while protecting the right to practice our sacred ceremonies without persecution. This exemption means the church can fully embrace its religious offerings, including the Ayahuasca ceremonies we’ve long prayed for.”

Keep reading

Trump’s VA Secretary Touts Being ‘One Of The First’ In His Role To Support Psychedelic Medicine For Veterans

The head of the U.S. Department of Veteran Affairs (VA) is touting the fact that he’s “one of the first” secretaries of the agency with a commitment to exploring psychedelics as a potential therapy option for veterans.

During a pair of hearings before the House Veterans’ Affairs and Appropriations Committees on Thursday, VA Secretary Doug Collins was asked about psychedelics issues by multiple GOP lawmakers, fielding questions about his intent to facilitate research in hopes of securing access for the veteran community.

At the Veterans Affairs Committee hearing, Rep. Jack Bergman (R-MI)—co-chair of the Congressional Psychedelic Advancing Therapies (PATH) Caucus—asked whether Collins had “any visibility” about the status of VA-supported psychedelics studies.

“We’re getting there,” Collins said. “I’m also probably one of the first of the [VA] secretaries who’ve actually decided that we will take a look at it. We’re not simply putting it off, and we’re going to do everything we possibly can, under the rules given to us by Congress, to actually continue that look. What we’re seeing so far is positive.”

“What we’re seeing so far in some of the studies that are related to VA, and also outside of VA as well,” he said, “is that there has been—especially when it comes to [post-traumatic stress disorder], and also traumatic brain injury and others—we’re seeing some actual positive outcomes there, especially when it is coupled with intense counseling. And I think that’s the one of the keys that we look forward to.”

Keep reading

Texas House Approves Bill To Study Psychedelic-Assisted Therapy And Make Recommendations For Legal Access

The Texas House of Representatives on Tuesday gave initial approval on Wednesday to a bill that would establish a state-backed study into the use of psilocybin, MDMA and ketamine to treat conditions such as PTSD and depression.

Lawmakers voted 98–41 to pass HB 4014, from Rep. John Bucy III (D), on second reading. A third reading vote on final passage, expected soon, would send the measure to the Senate.

The proposal is designed to help prepare the state for what supporters see as the eventual federal approval of psychedelic-assisted therapy. In its current form, it would create a study program under the state Health and Human Services Commission, which would assess clinical trials and published literature into the efficacy of psychedelics—specifically MDMA, psilocybin and ketamine—as a treatment PTSD, depression and other mental health disorders.

Officials would also review U.S. Food and Drug Administration (FDA) actions around the therapies, evaluate treatment guidelines and make recommendations to eventually ensure legal access for Texas patients.

“This bill will prepare Texas for the safe and efficient integration of psychedelic therapies into its healthcare system,” Bucy said on the House floor, “ensuring that Texans struggling with PTSD, depression and other mental health conditions have safe, affordable access to innovative treatment upon FDA approval.”

By December 1, 2026, the commission would need to provide a report to state lawmakers with results of the study as well as “any recommendations for legislative or other action necessary to ensure patient access to psychedelic therapies for treatment of post-traumatic stress disorder, depression, and other co-occurring conditions after those therapies are approved by the United States Food and Drug Administration.”

Keep reading

Hawaii Bill To Support Psychedelic Therapy—Passed By Both Senate And House—Is Dead For The Session

A Hawaii bill to support research into psychedelic-assisted therapies that had passed both chambers of the legislature in different forms missed a legislative deadline and is now dead for the session, its sponsor tells Marijuana Moment.

SB 1042, from Sen. Chris Lee (D), was scheduled for a conference committee meeting, with lawmakers from both legislative chambers set to hammer out differences between versions of the bill passed by the House and Senate.

“Unfortunately, we ran out of time was the bottom line,” Lee said in a brief phone interview. “And that happened to a slew of bills, not just this one.”

While the proposal won’t move forward this year, the senator said the conversation this session will set the stage for a renewed effort in 2026.

“The great thing is, we had agreement on the final language in the bill,” Lee said. “So I think picking up next year from there will give us the ability to identify a clear path forward.”

Keep reading

Decline Of Christianity Sparks Rise In Claims For Religious Protections Of Psychedelics

In February, a group called Singularism scored a troubling victory under the Utah Religious Freedom Restoration Act (RFRA), claiming police violated their rights by confiscating otherwise illegal magic mushrooms (psilocybin) used for tea ceremonies and their “scriptures” (recorded insights during trips). A mental health counselor had allegedly formed the organization to alleviate suffering and facilitate practitioners’ (called “voyagers”) connections with themselves and God.

A federal judge ordered the return of the items, rejecting the government’s argument that Singularism was “essentially a drug-dealing business in a minister’s robe.” The judge further found that Singularism held sincere religious beliefs and that each day the group was “deprived of the sacrament they suffer harm to their religious exercises.” Although the judge noted that individuals could perhaps achieve the same experiences from meditation, as opposed to illegal drugs, she said “most people do not have that luxury of time,” accurately distilling the zeitgeist of American obsession with a quick fix. And then she called it religion.

Litigation continues, but meanwhile, the decision sets a disturbing precedent. And a movement is afoot to capitalize on the win. Led by well-funded educated elites that includes scholars, lawyers, religious leaders, and entrepreneurs, the goal is obtaining widespread U.S. legalization of psychedelics.

How did we get here?

During the 21st century, the percentage of Americans attending religious services steadily shrank, while the percentage of those claiming no religion more than doubled. Christianity in particular has been in rapid decline. In 2007, 78 percent of U.S. adults identified as Christians; in 2024, that number had dropped to 62 percent.

Keep reading

Psychedelics May Reset Brain-Immune Link Driving Fear and Anxiety

A new study suggests that fear and the immune system are connected in previously unknown ways. Researchers at Mass General Brigham found that the immune system can influence stress and fear behaviors by changing how brain cells communicate.

The investigators further showed that psychedelic treatments could target these neuroimmune interactions and reduce stress-induced fear in preclinical models and found similar results in human tissue samples.

Results are published in Nature.

“Our study underscores how psychedelics can do more than just change perception; they can help dial down inflammation and reset brain-immune interactions,” said corresponding author Michael Wheeler, PhD, of the Gene Lay Institute of Immunology and Inflammation as well as the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital (BWH), a founding member of the Mass General Brigham healthcare system.

“This could reshape how we think about treatment for inflammatory disorders and conditions like anxiety and depression.”

Prior research has shown immune signaling can drive the development of neuropsychiatric diseases such as major depressive disorder (MDD). However, the ways that specific immune mechanisms can also affect behaviors due to chronic stress or MDD remained unclear.

Using a mouse model of chronic stress, the researchers determined that increased crosstalk between cells in the amygdala, or the brain’s fear center, boosted fear behaviors, elevated inflammatory signaling, and activated fear-promoting amygdala neurons.

Furthermore, inflammatory immune cells called monocytes migrated from other parts of the body to the brain meninges during chronic stress. The research team demonstrated that artificially manipulating these cells impacted fear behaviors.

Treating stressed mice with psilocybin and MDMA prevented monocytes from accumulating in the brain and lowered fear behaviors.

Keep reading

Microdosing Psychedelics as Treatment Could Increase Flexible Thinking

One small dose of a psychedelic compound could help brains better adapt to changing circumstances, potentially improving treatments for those struggling with depression, PTSD, and neurodegenerative diseases, according to experiments conducted in mice. The results of the study were reported in the journal Psychedelics.

“What makes this discovery particularly significant is the sustained duration of cognitive benefits following just one psychedelic dose,” Omar J. Ahmed, a psychology researcher at the University of Michigan and a co-author of the study, said in a press release. “We observed enhanced learning adaptability that persisted for weeks, suggesting these compounds may induce lasting and behaviorally meaningful neuroplasticity changes in the prefrontal cortex.”

Measuring Cognitive Flexibility

Figure 1. Experimental timeline and overview. (A) Experimental timeline. (B) Schematic of the SEQFR2-forward protocol. Mice have to sequentially poke left and then right within 30 s to earn a reward pellet. (C) Schematic of the SEQFR2-reversal protocol. Mice now are required to poke right and then left within 30 s to get a reward pellet. (Image Credit: Omar J Ahmed)

In the experiments, researchers treated mice with a single dose of a potent hallucinogen called 25CN-NBOH. That chemical binds very specifically to a serotonin receptor, then activates it. Serotonin receptors are often associated with depression.

Mice treated with the compound performed better than the mice that were not. The improvements lasted two to three weeks following administration. The results were similar in both male and female mice.

The researchers essentially tested how well they could adapt to changes in rules required to perform a particular task. Such tests are considered standard ways to measure what scientists call “cognitive flexibility” — the ability to try new approaches to accomplish the same job.

The mice treated with the psychedelic showed a better ability to adapt than ones who received a saline solution instead. The psychedelic mice also performed their tasks both more efficiently and more accurately.

Keep reading

Iowa House Passes Bill To Legalize Medical Use Of Psilocybin

The Iowa House passed legislation Monday to legalize the use of psilocybin, the psychoactive compound found in “magic mushrooms,” for psychiatric treatment through a state program.

House File 978, passed 84–6, would establish a Psilocybin Production Establishment Licensing Board within the Iowa Department of Health and Human Services (DHHS), operating in a similar fashion to the existing Medical Cannabidiol Advisory Board that oversees Iowa’s medical cannabis program. The board would grant licenses for the production and administration of products with psilocybin to people with certain mental health needs in the state.

The bill also sets new requirements for who can access the substance, including an age 21 restriction and limit of 5,000 patients who can be recommended psilocybin treatment.

Rep. John Wills (R-Spirit Lake), the floor manager for the bill, said he would not have guessed that he would be involved in a bill on psilocybin before this year because “it’s just not something that I’m into.” But he said after learning more about the effectiveness of psilocybin treatment for post-traumatic stress disorder (PTSD), he believed the program will help people suffering in Iowa, like military veterans, law enforcement officers and other groups that face high rates of PTSD.

He said the bill requires people to receive psilocybin in a clinical environment with psychiatric support. In this environment, he said, the drug has been shown to allow people to “relive” their trauma in a controlled, safe space, and be able to resolve or lessen the impacts of PTSD. Wills said he believes this method could help address the high suicide rates of veterans and others suffering from the disorder, and offers a better alternative to other forms of PTSD treatment currently available.

“I will tell you, right now the only option these veterans have, the only option these people with PTSD have, is to be on mind-altering, life-altering drugs for the rest of their life,” Wills said.

Keep reading

Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy

A Texas House committee took testimony on Monday about two bills designed to prepare the state to provide swift access to therapeutic psychedelics in the event of approval from the U.S. Food and Drug Administration (FDA).

One measure, HB 4014, would establish a state-backed study, in collaboration with university researchers, on the use of psychedelics to treat mental health disorders such as PTSD and depression. It would direct officials at the Department of State Health Services (DSHS) to make subsequent recommendations “to ensure patient access to psychedelic therapies” following FDA approval.

The other bill, HB 4813, would dictate that substances reclassified under federal law be similarly controlled under state law.

Members of the House Committee on Public Health heard from sponsors and public commenters at Monday’s hearing but did not take action on either bill.

Supporters said the proposals would work together to minimize delays to military veterans and others who stand to benefit from the potentially life-saving therapy.

“This is going to happen. This is coming,” Rep. John Bucy III (D), sponsor of HB 4014, said of what many described as impending FDA approval of psychedelic therapy. “This is the study bill to make sure we’re ready when it comes to implement.”

Bucy’s measure would establish a state-backed study into the use of psychedelics to treat mental health disorders, such as PTSD and depression, in consultation with researchers at Baylor College of Medicine and the University of Texas at Austin’s Center for Psychedelic Research and Therapy.

The project would include an assessment of clinical trials and published literature into the efficacy of psychedelics—specifically MDMA, psilocybin and ketamine—as a treatment PTSD, depression and other mental health disorders.

Officials would also review FDA actions around the therapies, evaluate treatment guidelines and make recommendations to eventually ensure legal access for Texas patients.

In a subsequent report, due by December 1, 2026, DSHS would need to “recommend legislative or other actions necessary to ensure patient access to psychedelic therapies following approval by the United States Food and Drug Administration, including considerations of provider availability, affordability, accessibility, training and licensure, and other regulatory requirements.”

Keep reading

Nevada Senate Passes Joint Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research

The Nevada Senate has approved a joint resolution that calls on Congress to reschedule certain psychedelics, provide protections for people using the substances in compliance with state law and streamline research.

About a week after the legislation from Sen. Rochelle Nguyen (D) cleared committee, the full chamber passed it in an 18-2 vote on Friday. It now moves to the Assembly for consideration.

Nguyen said on the floor that the proposal “sets forth the argument that certain research and therapeutic trials have demonstrated promising results for the use of these substances in the treatment of disorders such as traumatic brain injury, post-traumatic stress disorder, certain depressive disorders and other mental health conditions.”

“The measure notes the low abuse potential for classic psychedelics and highlights their safety in therapeutic session settings,” she said, adding that “SJR 10 expresses Nevada’s continued support for expanded research opportunities…and urges Congress and the appropriate federal agencies to increase related funding” for psychedelic medicines.

Keep reading